Paresh Vyas
MRCP FRCP FRCPath FMedSci
Professor of Haematology
- Consultant Physician
Normal and Leukaemic stem/progenitor cell biology
Our aim is to characterise the heterogeneous populations of leukaemia propagating cells in adult and childhood Acute Myeloid Leukaemia (AML) at functional, genetic, epigenetic and molecular levels, eventually at a single cell level, to improve our basic understanding of leukaemia initiation and propagation. The ultimate aim is to translate this knowledge to improve survival rates in patients.
Biography
Paresh Vyas is Professor of Haematology at the University of Oxford. He studied medicine at Cambridge then Oxford. After completing his medical and haematology training in London, he did his PhD with Professor Doug Higgs and Professor Sir David Weatherall at the MRC Molecular Haematology Unit, Oxford. A three-year post-doctoral fellowship with Professor Stuart Orkin at Harvard University followed. He is a research-active Consultant Haematologist with a clinical practice in myeloid disorders: myelodysplastic syndrome, MDS, acute myeloid leukaemia, AML, and myeloproliferative disorders, MPD, as well as allogeneic stem cell transplant. His research in the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, focuses on molecular and cellular biology of AML and MDS with specific interest in purification and therapeutic targeting of myeloid stem cells. He studies single cell biology in normal and leukaemic haemopoiesis. He is on the UK AML and MDS clinical trial groups.
Key publications
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy
Journal article
Turkalj S. et al, (2026), Blood, 147, 613 - 632
Human haematopoietic stem cells remember inflammatory stress
Journal article
Zeng AGX. et al, (2026), Nature
Clonal tracing with somatic epimutations reveals dynamics of blood ageing
Journal article
Scherer M. et al, (2025), Nature
Detecting and quantifying clonal selection in somatic stem cells
Journal article
Körber V. et al, (2025), Nature Genetics
Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1
Journal article
Agarwal P. et al, (2025), Nature
Risk Stratification in Older Intensively Treated Patients With AML
Journal article
Versluis J. et al, (2024), Journal of Clinical Oncology, 42, 4084 - 4094
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging
Journal article
Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17
Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved
Journal article
Aksöz M. et al, (2024), Science Immunology, 9
GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells
Journal article
Turkalj S. et al, (2023), Cell Stem Cell, 30, 722 - 740.e11
C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor
Journal article
Di Genua C. et al, (2020), Cancer Cell, 37, 690 - 704.e8
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome
Journal article
Labuhn M. et al, (2019), Cancer Cell, 36, 123 - 138.e10
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Journal article
Quek L. et al, (2018), Nature Medicine, 24, 1167 - 1177